A federal jury in Delaware found that Amgen and its acquired Teneobio willfully infringed an antibody patent owned by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed. The jury ordered Amgen to pay more than $20 million. The dispute centers on an antibody patent tied to Harbour’s portfolio, and the decision adds pressure for Amgen’s downstream IP strategy and product development planning. Amgen’s acquisition of Teneobio has also increased focus on how post-merger liabilities are managed. While the damages figure is set by the jury, further procedural steps—such as post-trial motions and appeals—will determine the case’s ultimate impact on Amgen’s commercialization or any potential licensing outcomes.